scholarly journals Climacteric syndrome. A nutritional approach to treatment

2020 ◽  
Vol 3 (3) ◽  
pp. 189-193
Author(s):  
L.V. Saprykina ◽  
◽  
M.R. Narimanova ◽  
D.M. Ibragimova ◽  
◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Hormonal Treatment ◽  
Biologically Active ◽  
Climacteric Syndrome ◽  
Protective Effects ◽  
Female Sex Hormones ◽  
Active Supplement ◽  
Almost All ◽  
Menopause Hormone Therapy

Female sex hormones are of crucial importance for a woman’s life. Almost all women over 40 irrespective of their origin or social status begin to experience physical, psychologic, and emotional problems. Menopause hormone therapy (MHT) is considered the most effective option to improve various symptoms of climacteric syndrome. Non-hormonal treatment can be an alternative to MHT to relieve the symptoms of climacteric symptoms in pre- and postmenopausal women, in particular, in contraindications or reluctance to take MHT. The paper addresses recent findings on the effects of soy isoflavones, β-alanine, tryptophan, and vitamins on tissues and the quality of life of pre- and postmenopausal women. Mense® (JC «Akvion»), a biologically active supplement that contains phytoestrogens, vitamins, and amino acids, is characterized by a variety of protective effects in pre- and postmenopausal periods. This biologically active supplement can be recommended for women with the symptoms of climacteric syndrome as a pretreatment during the screening before prescribing MHT, a dietary modification in contraindications or refusal of MHT, and/or an effective component of the complex treatment for climacteric syndrome.KEYWORDS: perimenopause, postmenopause, non-hormonal treatment, menopause hormone therapy, vasomotor symptoms, phytoestrogens, vitamins.FOR CITATION: Saprykina L.V., Narimanova M.R., Ibragimova D.M. Climacteric syndrome. A nutritional approach to treatment. Russian Journal of Woman and Child Health. 2020;3(3):189–193. DOI: 10.32364/2618-8430-2020-3-3-189-193.

scholarly journals SARS-Cov-2 Infection in Postmenopausal Women. New Data on Menopause Hormone Therapy

2022 ◽  
Author(s):  
Laura Baquedano ◽  
Javier Navarro ◽  
Yasmina José ◽  
Alexander Tristancho ◽  
Ana Ruiz ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Hospital Admission ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Protective Factor ◽  
Positive Impact ◽  
Respiratory Disorders ◽  
The Mean ◽  
Menopause Hormone Therapy

Abstract ObjectiveTo address the factors involved in hospital admission and medical follow up in postmenopausal women with COVID-19 diagnosis.MethodsRetrospective observational study. Postmenopausal women aged between 40-70 years since September 2020 until June 2021 with COVID-19 diagnosis were included. Of the 300 women cohort, 50 were receiving menopause hormone therapy (MHT)Results 288 patients were analyzed. The mean age was 56.20 years (+/-6.06y SD). Age (p=0.030), High blood pressure (HBP) (p=0.002), respiratory disorders (p=0.003), depression (p=0.028) and fibromyalgia (p=0.030) were associated with a greater risk for hospital admission, while MHT was found as a protective factor (p=0.042). Being a health professional (p<0.001), HBP (p=0.029), respiratory disorders (p=0.022), vitamin D deficiency (p=0.010), depression (p=0.005) and fibromyalgia (p=0.001) were related with a longer follow up while MHT was related with a shorter one (p=0.010). Regression analysis showed that HBP and respiratory disorders acted as independent factors for hospital admission while MHT and fibromyalgia were for the length of follow up. ConclusionsMHT has a positive impact in postmenopausal women with SARS-CoV-2 infection. HBP and respiratory disorders are associated with a higher risk of hospital admission of these patients.

scholarly journals TOFISOPAM: PROSPECTS FOR NON-HORMONAL THERAPY OF NEURO-VEGETATIVE AND PSYCHO-EMOTIONAL DISORDERS ASSOCIATED WITH MENOPAUSAL SYNDROME

2017 ◽  
pp. 88-91 ◽  
Author(s):  
Y. E. Dobrokhotova ◽  
L. V. Saprykina
Keyword(s):  
Hormone Therapy ◽  
Emotional Disorders ◽  
Hormonal Therapy ◽  
Hormonal Treatment ◽  
Climacteric Syndrome ◽  
Efficacy And Safety ◽  
Review Of Literature ◽  
Menopausal Syndrome ◽  
Number Of Factors ◽  
Perimenopausal Women

Despite the proven effect of menopausal hormone therapy on menopausal syndrome, a number of factors prevent perimenopausal women from receiving the treatment. The article is a review of literature on the possibility of non-hormonal treatment with tofisopam for neuro-vegetative and psycho-emotional disorders associated with climacteric syndrome. The article tells about the efficacy and safety of the drug taking into account its pharmacodynamic properties.

scholarly journals Pituitary Adenomas in Transgender Individuals?

2019 ◽  
Vol 79 (1) ◽  
pp. 62-66
Author(s):  
Bette K Kleinschmidt-DeMasters
Keyword(s):  
Hormone Therapy ◽  
Pituitary Adenomas ◽  
Hormonal Treatment ◽  
High Dose ◽  
Chronic Hypertension ◽  
Gender Transition ◽  
Pituitary Mass ◽  
Tissue Specimens ◽  
Almost All ◽  
Male To Female

Abstract Transgender individuals may receive long-term hormonal treatment as part of their sexual transition; limited literature has suggested that they consequently may be predisposed to development of prolactinomas. We questioned whether we had encountered such cases. Pathology databases were searched for the years 2000–2019 for tissue specimens from transgender individuals; Sixty surgical specimens from 58 individuals and 8 cytology specimens were identified. Two of these 60 were pituitary adenomas, neither of which were lactotroph adenomas (prolactinomas).The first occurred in a 71-year-old transgender male-to-female who had undergone high-dose hormone therapy, followed by orchiectomy 30 years prior. Chronic hypertension, dizziness, and vertigo prompted an endocrine workup which revealed elevated IGF-1 and prolactin; The pituitary mass proved to be a mixed somatotroph/lactotroph adenoma. The second occurred in a 53-year-old transgender male-to-female who was being evaluated by an endocrinologist prior to initiating hormone therapy for transition when a slightly elevated prolactin level was discovered. This pituitary macroadenoma proved to be a gonadotroph adenoma. The most common surgical specimens were 33 bilateral mastectomies, 13 hysterectomies, and 4 orchiectomies, almost all for gender transition purposes rather than medical conditions. Pathologists may wish to be aware of the occurrence of pituitary adenomas in transgender individuals, although the incidence is quite low.

scholarly journals Phytoestrogens in treatment of climacteric syndrome as an alternative to menopausal hormone therapy

2020 ◽  
Author(s):  
M. I. Mazitova ◽  
I. R. Talipova ◽  
R. R. Mardieva
Keyword(s):  
Hormone Therapy ◽  
Cardiovascular System ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
International Literature ◽  
Climacteric Syndrome ◽  
Sexual Symptoms ◽  
Age Related ◽  
Plant Compounds ◽  
Age Related Changes

Russian and international literature over the last 5 years was observed to study the use of phytoestrogens in treatment of climacteric syndrome. Effects of isoflavones as the main group of phytoestrogens on vasomotor, cognitive, psychological, urogenital and sexual symptoms as well as their action on the cardiovascular system, bones, and metabolic age-related changes are considered. Phytoestrogens administration is concluded to be perspective as an alternative to menopausal hormone therapy. It is reasonable to conduct further extensive researches to evaluate the effectiveness and safety of the use of the plant compounds in postmenopausal women.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

COMBINED CORRECTION OF THE CONDITION OF PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY

2020 ◽  
pp. 31-35
Author(s):  
Golovanov S.A. ◽  
Kuznetsov I.A. ◽  
Rasulov M.M.
Keyword(s):  
Posterior Wall ◽  
Biologically Active ◽  
Basic Therapy ◽  
Active Supplement ◽  
Functional Features ◽  
Dimensional Echocardiography ◽  
Stage 1 ◽  
Two Dimensional Echocardiography ◽  
Lipid Spectrum ◽  
Diastolic Functions

Patients from 30 to 50 years old, suffering from arterial hypertonia of stage 1-2 and obesity of 1-2 degree, were exam-ined. Pharmacological correction of cardiovascular disorders and changes in lipid metabolism with the use of dietary supplements "Triastin" against the background of basic therapy of patients with AH and OB with enalapril was car-ried out. In addition to the basic therapy, biologically active supplement Triastin was used in the amount of 2 cap-sules per day for 21 days in 2 cycles for 6 months as an additional hypolipidemic agent. Anthropometric research was carried out using unified methods. Obesity was assessed, as well as the lipid spectrum of the blood. The systolic and diastolic functions of the left ventricle, the size of the aorta, atria and right ventricle, the thickness of the interventric-ular septum in diastole (TMZhPd), the thickness of the posterior wall in diastole (TZSD) were determined using two-dimensional echocardiography. The study revealed a more pronounced and stable decrease in the level of blood pres-sure, lipid profile and side effects of basic therapy, improved myocardial remodeling and its functional features.

Sign in / Sign up

Export Citation Format

Share Document